Article Type
Changed
Mon, 06/22/2020 - 11:04

Key clinical point: Periconceptional rituximab is a highly effective and safe treatment for women with suboptimally controlled multiple sclerosis (MS).

Major finding: Among 38 live births, 3 deliveries were preterm (including 1 set of twins), 1 baby was admitted for perinatal ischemic stroke, and 1 twin died after 6 days from an intraventricular hemorrhage. Fifteen women reported at least one first-trimester miscarriage, of whom 8 had a history of infertility. No stillbirths, chorioamnionitis, or major malformations were recorded. Only 2 women experienced relapses, one during pregnancy and the other postpartum.

Study details: The data come from a study of 55 women with MS (74 pregnancies) treated with at least 1 dose of rituximab infusion before conception.

Disclosures: This study was supported in part by the Patient-Centered Outcomes Research Institute.

Some of the investigators reported receiving research grants from multiple pharmaceutical companies.

Citation: Smith JB et al. Neurol Neuroimmunol Neuroinflamm. 2020 May 01. doi: 10.1212/NXI.0000000000000734.

Publications
Topics
Sections

Key clinical point: Periconceptional rituximab is a highly effective and safe treatment for women with suboptimally controlled multiple sclerosis (MS).

Major finding: Among 38 live births, 3 deliveries were preterm (including 1 set of twins), 1 baby was admitted for perinatal ischemic stroke, and 1 twin died after 6 days from an intraventricular hemorrhage. Fifteen women reported at least one first-trimester miscarriage, of whom 8 had a history of infertility. No stillbirths, chorioamnionitis, or major malformations were recorded. Only 2 women experienced relapses, one during pregnancy and the other postpartum.

Study details: The data come from a study of 55 women with MS (74 pregnancies) treated with at least 1 dose of rituximab infusion before conception.

Disclosures: This study was supported in part by the Patient-Centered Outcomes Research Institute.

Some of the investigators reported receiving research grants from multiple pharmaceutical companies.

Citation: Smith JB et al. Neurol Neuroimmunol Neuroinflamm. 2020 May 01. doi: 10.1212/NXI.0000000000000734.

Key clinical point: Periconceptional rituximab is a highly effective and safe treatment for women with suboptimally controlled multiple sclerosis (MS).

Major finding: Among 38 live births, 3 deliveries were preterm (including 1 set of twins), 1 baby was admitted for perinatal ischemic stroke, and 1 twin died after 6 days from an intraventricular hemorrhage. Fifteen women reported at least one first-trimester miscarriage, of whom 8 had a history of infertility. No stillbirths, chorioamnionitis, or major malformations were recorded. Only 2 women experienced relapses, one during pregnancy and the other postpartum.

Study details: The data come from a study of 55 women with MS (74 pregnancies) treated with at least 1 dose of rituximab infusion before conception.

Disclosures: This study was supported in part by the Patient-Centered Outcomes Research Institute.

Some of the investigators reported receiving research grants from multiple pharmaceutical companies.

Citation: Smith JB et al. Neurol Neuroimmunol Neuroinflamm. 2020 May 01. doi: 10.1212/NXI.0000000000000734.

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Mon, 06/22/2020 - 11:00
Un-Gate On Date
Mon, 06/22/2020 - 11:00
Use ProPublica
CFC Schedule Remove Status
Mon, 06/22/2020 - 11:00
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge